Trump administration MFN drug-pricing policy reaches voluntary deals with 17 pharma firms

The White House said in May 12 materials that its most-favored-nation drug-pricing policy has secured voluntary agreements with 17 global pharmaceutical companies and would save federal and state Medicaid programs $64.3B over ten years. Industry resistance continues, however, with list prices for 872 branded drugs rising a median 4% so far in 2026.